Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevention of Cardiogenic Shock After Acute Myocardial Infarction.
Vanhaverbeke M, Bogaerts K, Sinnaeve PR, Janssens L, Armstrong PW, Van de Werf F. Vanhaverbeke M, et al. Among authors: bogaerts k. Circulation. 2019 Jan 2;139(1):137-139. doi: 10.1161/CIRCULATIONAHA.118.036536. Circulation. 2019. PMID: 30586685 Review. No abstract available.
ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up.
Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F; STREAM investigators. Sinnaeve PR, et al. Among authors: bogaerts k. Circulation. 2014 Sep 30;130(14):1139-45. doi: 10.1161/CIRCULATIONAHA.114.009570. Epub 2014 Aug 26. Circulation. 2014. PMID: 25161043 Clinical Trial.
The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients.
Armstrong PW, Bogaerts K, Welsh R, Sinnaeve PR, Goldstein P, Pages A, Danays T, Van de Werf F; STREAM 2 Study Groups (appendix). Armstrong PW, et al. Among authors: bogaerts k. Am Heart J. 2020 Aug;226:140-146. doi: 10.1016/j.ahj.2020.04.029. Epub 2020 May 15. Am Heart J. 2020. PMID: 32553932
Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction.
Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Armstrong PW, et al. Among authors: bogaerts k. N Engl J Med. 2013 Apr 11;368(15):1379-87. doi: 10.1056/NEJMoa1301092. Epub 2013 Mar 10. N Engl J Med. 2013. PMID: 23473396 Free article. Clinical Trial.
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, Ardissino D, Vahanian A, Pehrsson K, Armstrong P, Van de Werf F; ASSENT-2 Investigators. Sinnaeve P, et al. Among authors: bogaerts k. Am Heart J. 2003 Jul;146(1):27-32. doi: 10.1016/S0002-8703(03)00117-0. Am Heart J. 2003. PMID: 12851604 Clinical Trial.
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
Sinnaeve PR, Alexander JH, Bogaerts K, Belmans A, Wallentin L, Armstrong P, Adgey JA, Tendera M, Diaz R, Soares-Piegas L, Vahanian A, Granger CB, Van De Werf FJ. Sinnaeve PR, et al. Among authors: bogaerts k. Am Heart J. 2004 Jun;147(6):993-8. doi: 10.1016/j.ahj.2003.12.028. Am Heart J. 2004. PMID: 15199346 Clinical Trial.
Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS.
Sinnaeve PR, Huang Y, Bogaerts K, Vahanian A, Adgey J, Armstrong PW, Wallentin L, Van de Werf FJ, Granger CB; ASSENT-3 and ASSENT-3 PLUS investigators. Sinnaeve PR, et al. Among authors: bogaerts k. Am Heart J. 2006 Oct;152(4):684.e1-9. doi: 10.1016/j.ahj.2006.07.005. Am Heart J. 2006. PMID: 16996833
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysis.
Sinnaeve PR, Ezekowitz JA, Bogaerts K, Droogne W, Jarai R, Huber K, Granger CB, Desmet WJ, Armstrong PW, Van de Werf FJ; ASSENT-4 PCI Investigators. Sinnaeve PR, et al. Among authors: bogaerts k. Eur Heart J. 2009 Sep;30(18):2213-9. doi: 10.1093/eurheartj/ehp246. Epub 2009 Jul 8. Eur Heart J. 2009. PMID: 19586960 Clinical Trial.
Prediction of cardiogenic shock using plasma B-type natriuretic peptide and the N-terminal fragment of its pro-hormone [corrected] concentrations in ST elevation myocardial infarction: an analysis from the ASSENT-4 Percutaneous Coronary Intervention Trial.
Jarai R, Huber K, Bogaerts K, Sinnaeve PR, Ezekowitz J, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT-4 PCI investigators. Jarai R, et al. Among authors: bogaerts k. Crit Care Med. 2010 Sep;38(9):1793-801. doi: 10.1097/CCM.0b013e3181eaaf2a. Crit Care Med. 2010. PMID: 20562693 Clinical Trial.
145 results